中国实用外科杂志2017，Vol.37Issue(7)：755-760,6.DOI:10.19538/j.cjps.issn1005-2208.2017.07.12
美国约翰·霍普金斯医学院进展期胰腺癌治疗经验及研究趋势
Progress and experience about advanced pancreatic cancer at the Johns Hopkins
车旭 1黄小准 2陈建霖 2夏涛 3郑雷4
作者信息
- 1. 国家癌症中心中国医学科学院北京协和医学院肿瘤医院胰胃外科,北京100021
- 2. 国家癌症中心中国医学科学院北京协和医学院肿瘤医院深圳医院肝胆胰外科,广东深圳518116
- 3. 中山大学肿瘤防治中心附属肿瘤医院,广东广州510060
- 4. 浙江大学医学院,浙江杭州310058
- 折叠
摘要
Abstract
Current therapies for pancreatic cancer have limited effects. Precision medicine has shown great potential for clinical applications,include new pancreatic cancer classification based on genomics and transcriptomics,through a minimally invasive "liquid biopsy" to detect circulating tumor cells,circulating cell-free DNA,and exosomes,which are permited to monitor of the clonal evolution of individual pancreatic cancer during the course of treatment and disease progression. Various strategies are being tested in clinical trials in Johns Hopkins, examining genes that are involved in the metabolism of chemotherapeutic agents help to select a more accurate,higher response rate of chemotherapy. Based on tumor genome and transcriptome,the landscape of the pancreatic ductal adenocarcinoma genome is notable,study of mutant genes will be helpful in selecting the best treatment. Treatment selection based on host immune response,designed based on whole-exome sequencing of mutated genes,will facilitate further tailoring of vaccine therapies for individual patients,at present,the combination of pancreatic cancer vaccine and chemotherapy drugs has achieved some positive results,and further studies are being carried out.关键词
胰腺癌/精准医学/化学治疗/免疫治疗/基因组学Key words
pancreatic carcinoma/precision medicine/chemotherapy/immunotherapy/genomics分类
医药卫生引用本文复制引用
车旭,黄小准,陈建霖,夏涛,郑雷..美国约翰·霍普金斯医学院进展期胰腺癌治疗经验及研究趋势[J].中国实用外科杂志,2017,37(7):755-760,6.
